TLDR
- Boston Scientific stock dropped 2.3% in premarket trading after warning it will likely miss its Q3 and full-year 2026 guidance.
- The guidance warning is directly tied to the cyberattack discovered on August 25.
- The company previously forecast full-year sales growth of 5.5% to 6.5% and adjusted EPS of $3.28 to $3.32.
- BSX stock is down 50% year-to-date and 55% over the past 12 months, sitting far below its 52-week high of $109.50.
- TD Cowen kept its Buy rating and $56 price target, but the positive note was overshadowed by the formal financial warning.
Boston Scientific (BSX) stock dropped 2.3% to $46.68 in premarket trading on Tuesday after the company formally warned it will likely miss its earnings and sales guidance for Q3 and full-year 2026.
Boston Scientific Corporation, BSX
The warning is a direct result of the cyberattack the company disclosed on August 25. In a regulatory filing Tuesday, BSX said it is “unlikely to meet” its net sales growth and adjusted EPS guidance ranges for both the third quarter and the full year.
That is a harder stance than the company had taken previously, when it said the financial impact of the breach had not yet been determined.
At the end of July, Boston Scientific had guided for full-year sales growth of 5.5% to 6.5% and adjusted EPS of $3.28 to $3.32. For Q3, the company had forecast net sales growth of 3% to 5% and adjusted EPS of 80 to 82 cents.
Wall Street had been expecting full-year adjusted EPS of $3.30 on net sales of $21.35 billion, with Q3 EPS consensus at 81 cents and sales of $5.26 billion, according to FactSet.
The stock has had a rough year well before this latest news. BSX is down 50% year-to-date and has fallen 55% over the past 12 months. It is trading far below its 52-week high of $109.50 and closer to its 52-week low of $42.20.
Analyst Reactions
The guidance withdrawal adds more pressure to a stock that was already under scrutiny. Argus Research had previously downgraded BSX to Hold from Buy, pointing to growth concerns around the Watchman device and the U.S. electrophysiology franchise.
Baird, JPMorgan, and Bank of America had each trimmed their price targets after Q2 earnings and the initial cyberattack disclosure.
TD Cowen was the lone bright spot, reiterating its Buy rating and $56 price target. The firm noted that as of September 5, Boston Scientific’s major distribution centers were processing and shipping products at or above normal levels. That positive update, however, did little to soften the blow of Tuesday’s formal warning.
What Comes Next
Boston Scientific said it has not found evidence of ongoing unauthorized access to its systems, though the investigation is still active.
The company added that it expects to recover some portion of the lost revenue as operations ramp back up, customer orders are fulfilled, and backlogs are reduced.
The full financial impact of the attack is still not known. Boston Scientific plans to give a full update on its operational and financial outlook, including the cyberattack’s impact, during its Q3 earnings call on October 28.
Medtech peers Abbott and Medtronic have also dealt with cybersecurity incidents in 2026, keeping broader sector sentiment under pressure.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
